Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Purchases $256,050.00 in Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) CEO Jay R. Luly purchased 45,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The stock was bought at an average cost of $5.69 per share, with a total value of $256,050.00. Following the completion of the purchase, the chief executive officer now owns 846,638 shares of the company's stock, valued at $4,817,370.22. This represents a 5.61 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Enanta Pharmaceuticals Price Performance

Shares of ENTA traded down $0.36 during trading on Friday, reaching $7.14. 419,301 shares of the company traded hands, compared to its average volume of 435,589. The stock has a 50-day simple moving average of $5.72 and a 200-day simple moving average of $9.40. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.71 and a twelve month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. As a group, analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.05 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. StockNews.com cut shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, February 11th. JMP Securities restated a "market outperform" rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Robert W. Baird dropped their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Enanta Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $17.25.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. acquired a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $26,000. Tower Research Capital LLC TRC lifted its stake in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 2,274 shares during the last quarter. US Bancorp DE lifted its stake in Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after buying an additional 4,243 shares during the last quarter. Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals in the fourth quarter valued at $58,000. Finally, Wells Fargo & Company MN grew its holdings in Enanta Pharmaceuticals by 69.6% during the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock worth $91,000 after acquiring an additional 6,518 shares during the period. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.